Huadong Medicine announced positive Phase 3 results for its oral small-molecule GLP-1 receptor agonist HDM1002, showing significant weight loss in Chinese patients with obesity.
Huadong Medicine's oral GLP-1 candidate HDM1002 achieved robust weight loss with a clean safety profile, paving the way for an NDA submission and potential market disruption.
Free preview — more China A-share & HK research · About Us · Legal & Privacy